Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 7, 2324709619893548

Primary Central Nervous System Lymphoma in an Immunocompetent Patient Presenting as Multiple Cerebellar Lesions: A Case Report and Review of Literature


Primary Central Nervous System Lymphoma in an Immunocompetent Patient Presenting as Multiple Cerebellar Lesions: A Case Report and Review of Literature

Gliceida M Galarza Fortuna et al. J Investig Med High Impact Case Rep.


Primary central nervous system (CNS) lymphoma (PCNSL) is an uncommon extranodal non-Hodgkin lymphoma often presenting as a single brain lesion within the CNS. On histopathological evaluation of PCNSL a positive CD10, which is frequently observed in systemic diffuse large B-cell lymphoma, is present in approximately 10% of PCNSL. We describe a case of CD10-positive PCNSL presenting with multiple posterior fossa enhancing lesions in an immunocompetent older woman with a history of breast cancer successfully treated by the RTOG 0227 protocol consisting of pre-irradiation chemotherapy with high-dose methotrexate, rituximab, and temozolomide for 6 cycles, followed by low-dose whole-brain radiation and post-irradiation temozolomide.

Keywords: CD10; brain tumor; cerebellar tumor; lymphoma; primary CNS lymphoma.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.


Figure 1.
Figure 1.
Brain MRI showing multiple enhancing brain lesions including a 0.7-cm right superior anterior cerebellar parenchymal lesion (A, arrow), 0.3-cm and 0.2-cm left paramedian cerebellar vermian lesions (A, dashed arrow), a 1.9-cm superior right cerebellar lesion with mass effect and surrounding vasogenic edema causing partial effacement of the right aspect of the fourth ventricle (B), and a 0.2-cm left thalamic lesion (C, arrow).
Figure 2.
Figure 2.
Brain biopsy showing a cellular infiltrate with necrosis and perivascular preservation (A) composed of large lymphoid cells with centralistic morphology and numerous apoptotic bodies (B), immunoreactive for CD-20 (C), Bcl-6 (D), and CD-10 (E) consistent with a DLBCL of germinal center phenotype. The lymphoma exhibited a high proliferation index (>95%).
Figure 3.
Figure 3.
Brain MRI after 6 cycles of chemotherapy completion showing interval resolution of the multiple enhancing lesions in the posterior fossa. No evidence of residual or new foci of primary CNS lymphoma.

Similar articles

See all similar articles


    1. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105:1414-1418. - PMC - PubMed
    1. Phillips EH, Fox CP, Cwynarski K. Primary CNS lymphoma. Curr Hematol Malig Rep. 2014;9:243-256. - PMC - PubMed
    1. Rubenstein JL. Biology of CNS lymphoma and the potential of novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017:556-564. - PMC - PubMed
    1. Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35:2410-2418. - PMC - PubMed
    1. Shiels MS, Pfeiffer RM, Besson C, et al. Trends in primary central nervous system lymphoma incidence and survival in the US. Br J Haematol. 2016;174:417-424. - PMC - PubMed

LinkOut - more resources